In the realm of cancer treatment, the battle against non-small cell lung cancer (NSCLC) has been intensified with the advent of targeted therapies. Among the numerous medications available, alectinib and lorlatinib have emerged as prominent options for patients with advanced NSCLC, particularly those with ALK-positive mutations. This article aims to delve into a comparative analysis of these...